Literature DB >> 10529129

Natural history of hypercholesterolemia in systemic lupus erythematosus.

I N Bruce1, M B Urowitz, D D Gladman, D C Hallett.   

Abstract

OBJECTIVE: To determine the natural history of hypercholesterolemia in the first 3 years of disease in an inception cohort of patients with systemic lupus erythematosus (SLE) followed at a single center and to determine the influence of hypercholesterolemia on the subsequent development of coronary artery disease (CAD) related events.
METHODS: We identified patients who were seen at the University of Toronto lupus clinic within 1 year of diagnosis from January 1, 1974, to December 31, 1987, and who were seen at least once a year in the first 3 years. Patients were divided into 3 groups: Normal cholesterol: serum total cholesterol (TC) < 5.2 mmol/l throughout the 3 year period of study. Sustained hypercholesterolemia: at least one measurement of TC of > 5.2 mmol/l in each of the first 3 years at the clinic. Variable hypercholesterolemia: TC > 5.2 mmol/l in no more than 2 of the first 3 years of followup. Patients were followed from inception until the present day. The primary outcome was the time of the first CAD related event (myocardial infarction, angina, or sudden unexplained death).
RESULTS: One hundred thirty-four patients (118 women, 16 men) were studied: 33 (24.6%) had normal cholesterol, 54 (40.3%) had sustained hypercholesterolemia, and 47 (35.1%) had variable hypercholesterolemia. Using multiple logistic regression the best predictors of sustained hypercholesterolemia were cumulative dose of steroids, no antimalarial therapy, and age of onset of SLE > 35 years old. CAD related events occurred in 1 (3%) of the normal TC group, 3 (6.4%) of the variable group, and in 15 (27.8%) of the sustained group (p = 0.003), 79% of all CAD events occurred in the sustained group. The best predictors of CAD were sustained hypercholesterolemia, lung involvement, and age at onset of SLE > 35 years.
CONCLUSION: Within 3 years of diagnosis, 75.4% of patients with SLE had elevated TC, which was sustained in 40.3% of all patients. Older age at onset as well as increased cumulative dose of steroids and no antimalarial therapy are significant predictors of this group. It is this group that experiences the majority of CAD related events. Aggressive lipid lowering therapy should be targeted at such patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529129

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

Review 1.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

2.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study.

Authors:  M B Urowitz; D D Gladman; D Ibanez; Y Berliner
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

3.  Risk factors for coronary heart disease in connective tissue diseases.

Authors:  Awal Al Husain; Ian N Bruce
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

Review 4.  Atherosclerosis in systemic lupus erythematosus.

Authors:  George Stojan; Michelle Petri
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

5.  Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.

Authors:  J F Muñoz-Valle; M Vázquez-Del Mercado; S Ruiz-Quezada; E Oregón-Romero; R E Navarro-Hernández; J Ramírez-Barragán; G Martínez-Bonilla; G Bernard-Medina; B E Bastidas-Ramírez; B Ruiz-Madrigal; A Panduro
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

6.  Contemporary treatment of systemic lupus erythematosus: an update for clinicians.

Authors:  Maame B Amissah-Arthur; Caroline Gordon
Journal:  Ther Adv Chronic Dis       Date:  2010-07       Impact factor: 5.091

7.  Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study.

Authors:  Mandana Nikpour; Dafna D Gladman; Dominique Ibanez; Paula J Harvey; Murray B Urowitz
Journal:  Arthritis Res Ther       Date:  2010-06-30       Impact factor: 5.156

Review 8.  Epidemiology of atherosclerosis in systemic lupus erythematosus.

Authors:  Mandana Nikpour; Murray B Urowitz; Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

9.  Alpha-chlorofatty Acid and coronary artery or aorta calcium scores in women with systemic lupus erythematosus. A pilot study.

Authors:  Mary A Mahieu; Camelia P Guild; Carolyn J Albert; George T Kondos; James J Carr; Daniel Edmundowicz; David A Ford; Rosalind Ramsey-Goldman
Journal:  J Rheumatol       Date:  2014-08-01       Impact factor: 4.666

10.  Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients.

Authors:  Claudia R L Cardoso; Flávio V Signorelli; Jose A Papi; Gil F Salles
Journal:  Rheumatol Int       Date:  2007-09-04       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.